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Personalized medicine aims to utilize genomic information about patients to tailor treatment. Gene replacement therapy for ra-
re genetic disorders is perhaps the most extreme form of personalized medicine, in that the patients’ genome wholly determines 
their treatment regimen. Gene therapy for retinal disorders is poised to become a clinical reality. The eye is an optimal site for 
gene therapy due to the relative ease of precise vector delivery, immune system isolation, and availability for monitoring of 
any potential damage or side effects. Due to these advantages, clinical trials for gene therapy of retinal diseases are currently 
underway. A necessary precursor to such gene therapies is accurate molecular diagnosis of the mutation(s) underlying disease. 
In this review, we discuss the application of Next Generation Sequencing (NGS) to obtain such a diagnosis and identify dis-
ease causing genes, using retinal disorders as a case study. After reviewing ocular gene therapy, we discuss the application of 
NGS to the identification of novel Mendelian disease genes. We then compare current, array based mutation detection methods 
against next NGS-based methods in three retinal diseases: Leber’s Congenital Amaurosis, Retinitis Pigmentosa, and Star-
gardt’s disease. We conclude that next-generation sequencing based diagnosis offers several advantages over array based 
methods, including a higher rate of successful diagnosis and the ability to more deeply and efficiently assay a broad spectrum 
of mutations. However, the relative difficulty of interpreting sequence results and the development of standardized, reliable bi-
oinformatic tools remain outstanding concerns. In this review, recent advances NGS based molecular diagnoses are discussed, 
as well as their implications for the development of personalized medicine.  
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Personalized medicine is revolutionizing healthcare. Our 
impending ability to understand patient’s defects on the 
molecular level, and to specifically tailor treatment on the 
same scale, may allow the development of therapies to treat 
previously incurable diseases and improve treatment across 
the board [1]. Inherited ocular diseases, in particular, are 
ideal targets for gene therapy, and have been the subject of 
numerous clinical trials ([2–8], reviewed in [9]) and studies 
[10–15] for a number of reasons. First, the clinical and ge-
netic heterogeneity of ocular disorders makes it difficult to 
identify compounds that can treat all patients effectively, 
suggesting that tailored treatments may be necessary [16]. 
Second, a large number of genes underlying disease have 
been identified [17] that cumulatively account for a majority 
of cases [18–20], making it possible for accurate diagnosis 
at the molecular level. Third, gene therapy in the eye has 
been highly successful in both animals and humans. Since 
the eye is immune privileged [21], a weak immune reaction 
is trigged when a virus is injected in the eye [8], reducing 
the side effects of gene therapy and increasing transfection 
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efficiency. In this review, we first discuss current advances 
in the field of ocular gene therapy and how they necessitate 
improved diagnostics.  
1  Gene therapy 
1.1  Ocular gene therapy vectors 
Gene therapy, or the correction of a genetic default through 
the introduction of exogenous nucleic acids, was first per-
formed in mammals early in the 1970s using herpes simplex 
virus to treat mouse cells with a thymidine kinase enzyme 
deficiency [22]. The retina of the eye has several advantages 
for the application of gene therapy. It is immune isolated, 
and is visible and accessible to clinicians. This allows for 
relatively easy delivery of vector and non-invasive moni-
toring after application of the therapy [23]. Further, the 
compartmentalization of the eye allows for highly localized 
administration of vectors, typically in the form of modified 
viruses used to deliver genetic material of interest. These 
features minimize the risk of serious complications in ocular 
gene therapy. Indeed, despite numerous clinical trials, seri-
ous systemic problems in humans after ocular gene therapy 
have yet to be observed.  
A major breakthrough occurred with the discovery of 
Adeno-Associated Virus (AAV) as an effective transducing 
vector [24,25]. The DNA of therapeutic AAVs exists in cell 
as an episome, precluding concerns about insertional muta-
genesis and cancer. Further, AAV is not able to self-propa-     
gate, and generates a minimal immune response. Eleven 
different serotypes of AAV have been discovered so far 
[26], and modifications to these serotypes have further 
added to the variety of vectors [27,28]. Targeting studies, 
typically using GFP, found that various forms of AAV are 
able to transduce retinal ganglion cells [29,30], the retinal 
pigment epithelium(RPE) [4,31] and the inner retina [32]. In 
summary, through both natural variation and directed modi-
fication, AAV vectors currently exist with the capability of 
modifying most retinal cell types, including those most 
commonly associated with genetic retinal disease. This host 
of vectors has been utilized for gene therapy both in animals 
and humans.  
1.2  Animal studies 
Mammal models of retinal disease have existed since the 
1970s [10,11]. The 1990s saw the first successful applica-
tion of ocular gene therapy in vivo, which effectively de-
layed the onset of photoreceptor death in a mouse model of 
Retinitis Pigementosa (RP) with mutations in the enzyme 
βPDE [12]. These rd1 mice were administered sub-retinal 
injection of AAV2 containing wild type murine βPDE, re-
sulting in increased photoreceptor longevity. This and other 
early work showed the feasibility of gene therapy for reces-
sive ocular diseases [13], encouraging further work in the 
field.  
Substantial progress has subsequently been made through 
improvements in viral vectors and delivery systems, leading 
to an actual improvement of vision, rather than simply de-
layed degeneration [14,15]. For example, gene replacement 
was recently performed for the rd10 mouse model using 
AAV8. All treated eyes showed signs of improved visual 
function, including on an ERG and spectral domain optical 
coherence tomography, and benefits remained for at least 
six months [33]. AAV8 was used to successfully treat 
MERTK rats, which normally have RP, resulting in im-
proved vision for at least eight months [34]. Gene replace-
ment has succeeded in treating recessive retinal disorders in 
large animals, from dogs [35] to non-Human primates [36]. 
As illustrated by these cases, gene replacement in reces-
sive disorders has been highly successful. Additionally, 
successful ocular gene therapies resulting in improved vi-
sion have been performed in animal models of dominant 
(RP) [37], X-linked (retinoschisis, RP) [38,39], mitochon-
drial (Leber’s hereditary optic neuropathy) [40], and even 
complex retinal diseases (age-related macular degeneration 
(AMD)) [41].  
1.3  Human gene therapy 
Animal studies have led to a renaissance in human gene 
therapy, with the advent of clinical trials for the treatment of 
Stargardts, Leber’s Congenital Amaurosis (LCA), AMD 
and RP [2–4]. In 2008, three independent studies completed 
phase I clinical trials of used AAV2-driven gene replace-
ment to treat retinal degeneration caused by RPE65 muta-
tions [5–7]. The majority of participants reported improved 
vision. Further, re-administration of the therapeutic vector 
does not appear to reduce its efficacy, making gene therapy 
a potential long-term solution for both eyes [8]. 
Stem cell therapies, which may function on highly de-
generated tissues, are also undergoing clinical trials [42]. 
They operate by replacing damaged cell layers with new, 
undamaged tissue [43]. This could be done by converting 
cultured patient cells into Induced Pluripotent Cells (IPCs), 
which could then be differentiated into retinal precursor 
cells [44]. Optimally, gene therapy would be performed on 
the IPCs prior to their transplantation [45] to address the 
genetic defect in the patient’s original tissue. As in tradi-
tional gene therapy, application of this step would require 
high confidence molecular diagnosis, but it would allow 
restoration of vision in cases with highly degenerate retinas. 
In summary, gene therapy for a wide range of ocular dis-
orders is rapidly becoming a clinical reality. While gene 
therapy is on the road to success, a pre-requisite for its use 
is discovering the mutations that are causing disease in pa-
tients [46]. Therefore, obtaining a complete list of genes 
underlying the disease and accurately identifying disease 
causing mutations in each patient are prerequisites for per-
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sonalized treatment. 
2  Disease gene cloning through next-generation 
sequencing (NGS) 
In the past two decades, more than 185 genes associated 
with inherited eye diseases have been identified [17] (Figure 
1). However, much of this work depended on family based 
linkage analysis and positional cloning [47,48]. With lim-
ited numbers of large disease pedigrees, it is becoming in-
creasingly difficult to pinpoint novel genes using these 
methods. This challenge can be addressed by sequencing 
the genomes of patients with a shared disease, with the goal 
of finding shared rare mutations. 
The first case of successful application of this method 
was in 2009, when mutations in DODH were identified as 
the cause of Miller syndrome by sequencing just seven in-
dividuals, of which four were affected [49]. Since 2009, 
more than 100 genes responsible for Mendelian disorders 
have been identified through NGS based methods [50]. In 
ocular disease, numerous genes have been identified using 
NGS [5153]. This process is becoming increasingly robust 
as larger control databases and more advanced bioinformat-
ics techniques are developed. Details about NGS based gene 
identification and the resultant findings can be found in an 
excellent review, which concluded that WES will be an 
important tool in future gene cloning efforts [50].  
Indeed, a recently published theoretical model indicates 
that sequencing a reasonably sized patient cohort would 
allow identification of nearly all genes causing a significant 
fraction of cases of the disease. For example, by sequencing 
200 patients with the same recessive Mendelian disor-
der, >90% power can be achieved to identify genes causing 
the disease in at least 5% of the affected population (Figure 
2) [54]. Therefore, with the progress of large scale projects 
targeted to Mendelian disorders (http://www.genome.gov/ 
27546192) and rapid accumulation of NGS sequencing re-
sults, we expect that the vast majority of Mendelian disease 
genes can be identified in the near future. This success, 
however, will cause a rapid increase in the number of genes 
that must be surveyed to obtain a molecular diagnosis.  
3  Molecular diagnosis in retinal disease 
Finding causative mutations for retinal disease can be diffi-
cult due to the large number of genes responsible, as well as 
the complexity of the genotype phenotype relationship in 
these disorders. For example, LCA is caused by eighteen 
genes [53,55–72], and mutations in these genes can also 
cause RP, vitreoretinal degeneration, pigmented paravenous 
chorioretinal atrophy, Senior-Loken syndrome, congenital 
cone-rod synaptic disease, Joubert syndrome, Meckel syn-
drome, cone-rod dystrophy, and microphthalmia [73]. New 
connections are still being made [72,74]. Nonetheless, an 
accurate molecular diagnosis is essential, not only for gene 
therapy but also for genetic counseling, pathway specific 
drug prescription [16], and prognostics. The two most 
commonly used clinical mutation identification tools are 
Sanger sequencing and Allele specific Primer EXtention 
(APEX) arrays.  
Sanger sequencing is considered to be the golden stand-
ard for mutation identification due to its accuracy. However, 
because Sanger sequencing is labor intensive and has high 
per-base sequencing cost, it can be only effectively used to 
scan a limited number of exons for mutations, or to confirm 
mutations found by other methods. Given that 185 retinal 
disease genes have been identified to date, Sanger sequenc-
ing every exon potentially contributing to retinal disease is 
prohibitively costly and time-consuming. This difficulty 
drove the development of high throughput, array based gen-
otyping methods for retinal disease.  
APEX is an array based SNP genotyping technology [75] 
that is used to sequence the base pair following a designed 
oligonucleotide of choice. Since each spot on the array only 
sequences a single base pair, only known pathogenic bases 
are targeted. The current Asper Ophthalmics LCA array 
includes 780 disease-associated sequence variants identified 
in 15 LCA and early-onset RP genes [76]. This method is 
accurate, but is only able to detect novel mutations if they 
occur at the same position as a known mutation. Further, 
only a subset of all known LCA genes and mutations are 
tested. This process generates a successful diagnosis in 
~17%–32% of LCA cases [77,78].  
Similarly, three Asper Ophthalmics APEX panels exist 
for RP, each for a separate form of inheritance. For example, 
the latest dominant RP panel offered by Asper provides 
simultaneous detection of 414 known disease-associated 
variants in 16 genes, while their recessive RP panel screens 
594 known mutations in 19 genes [79]. APEX based diag-
nostics greatly increase diagnosis efficiency when screening 
a large number of mutations from multiple genes, allowing 
for high throughput analysis. However, since current arrays 
can only detect known mutations in a subset of known RP 
genes, successful diagnosis is only achieved in 15% of all 
RP cases [80,81]. Further, performing the test requires 
knowledge about the inheritance pattern of the patient, 
which is only available for about 50% of patients [82]. 
Molecular diagnosis of patients using current methods is 
either prohibitively expensive or suffers from very low ac-
curacy. In the following section, we will review molecular 
diagnosis using NGS based strategies for three common 
retinal diseases: LCA, RP, and Stargardt disease.  
3.1  NGS based molecular diagnosis in Leber’s Con-
genital Amaurosis 
LCA is the most extreme form of inherited retinal disease, 
as LCA patients typically have severe visual impairment or  
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Figure 1  The number of known retinal disease genes (red) and mapped loci (blue) responsible for retinal disease, graphed over time. Modified from: Ret-
Net, http://www.sph.uth.tmc.edu/RetNet/. 
 
Figure 2  The calculated power with a varying fraction of patients for which a given locus is responsible (R), ranging from 0.01 to 1, is shown. A, Power 
for detecting a recessive gene. B, Power for detecting a dominant gene. Other parameters are fixed to the default values: number of mutations after filter-
ing=300; total number of genes assayed=20000; sensitivity of detecting mutations=0.8; and the causative mutation occurs in an average sized gene. Note that 
power does not always increase monotonously with sample sizes (zigzag line patterns). The loss of power upon increase of sample size is related to discrete 
changes in the significance level cutoff tα of the test and thus very small test size, since the distribution of the test statistic is discrete. Modified from: Zhi D 
and Chen R. Statistical guidance for experimental design and data analysis of mutation detection in rare monogenic mendelian diseases by exome sequencing. 
PLoS One, 2012, 7(2): e31358. 
blindness within the first year of life. Other symptoms in-
clude congenital nystagmus, defective pupillary responses, 
and a reduced signal in electroretinograms (ERG) [83]. 
LCA is estimated to affect one in every 30000–80000 indi-
viduals and accounts for ~5% of all retinal dystrophies 
[84,85]. It is estimated that about 70% of European LCA 
cases are explained by known LCA genes [18], though this 
number is expected to be lower for different ethnicities 
[86,87].  
Interestingly, mutations in the same gene can cause either 
syndromic or non syndromic eye disease. For example, mild 
alleles in CEP290 cause LCA, while complete loss of 
CEP290 function leads to Joubert syndrome [58]. Also, the 
recently identified LCA gene KCNJ13 was previously re-
ported to cause vitreoretinal degeneration [72], a related but 
distinct disorder. These findings underscore the genetic het-
erogeneity and difficulty of genetic diagnosis in LCA.  
Compared with microarray based methods, NGS has a 
lower per base cost and is able to detect novel mutations 
and novel genes. When preceded by a capture array, which 
specifically isolates DNA of interest, NGS can efficiently 
sequence every base pair in a large area of interest. This 
flexibility allows NGS to frequently identify novel muta-
tions [88,89] in inherited human diseases. Indeed, Frauke 
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Coppieters et al. recently diagnosed LCA patients using 
DNA capture combined with NGS. They were able to con-
firm previously identified mutations, and found the causal 
mutations missed by arrays in 3 out 17 patients [90], an in-
crease in diagnosis rate of over 17%. 
Due to the genetic heterogeneity of LCA and low rates of 
diagnosis, it is evident that a portion of LCA is caused by 
mutations outside of known eye LCA genes. The high 
throughput nature of capture-NGS can be used to efficiently 
query large sets of genes to search for this missing inher-
itance. Indeed, utilizing a capture chip targeting all known 
retinal disease genes, recent work in our lab shows that a 
high percentage of LCA cases are indeed caused by muta-
tions in genes known to cause retinal disease, but previously 
unlinked with LCA (unpublished data).  
In summary, NGS based genetic diagnosis of LCA has 
several advantages over previous methods, but has the add-
ed challenge of properly interpreting NGS data. Also, due to 
LCA’s genetic heterogeneity, comprehensive screening 
every base in all known retinal disease genes is desirable. 
Currently, this can only be efficiently achieved with NGS.  
3.2  NGS based molecular diagnosis in RP 
Retinitis pigmentosa (RP) is a progressive retinal degenera-
tion, affecting about 1 in 4000 people worldwide [91]. Ini-
tially, rod photoreceptor cells begin to die. Patients at this 
stage develop early onset night blindness and tunnel vision. 
As the disease develops, the loss of rod cells begins to 
damage cone photoreceptors. Their degeneration causes a 
reduction of central and color vision and may lead to com-
plete blindness. The retinal pigment epithelium (RPE) is the 
third major type of cell that degenerates over the course of 
RP, in response to loss of photoreceptor cells. RPE cells 
release pigment granules as they degenerate, which often 
accumulate in a bone spicule configuration that further oc-
cludes vision. 
RP is highly heterogeneous, with autosomal recessive 
(ar), autosomal dominant (ad), X-linked, digenic, and mito-
chondrial forms. To date, 52 genes functioning in diverse 
biological pathways have been linked to RP [92]. Among 
them, genes involved in the phototransduction cascade ac-
count for a major portion of RP cases. Mutations in photo-
transduction-related genes RHO and PDE are responsible 
for 25% adRP cases and 8% of arRP cases, respectively 
[93,94]. Because of its genetic heterogeneity, an accurate 
molecular diagnosis is challenging. Even with decades of 
improvement, current diagnostics including Sanger se-
quencing and APEX still have many limitations.  
Recent developments in NGS and DNA capture tech-
nology provide a potential new approach to molecular di-
agnosis in RP. Indeed, it has been shown to have many ad-
vantages over current diagnostic methods [19,20]. First of 
all, NGS based molecular diagnosis of RP is the most com-
prehensive molecular diagnostic method available. By 
screening of both known and novel mutations in all known 
RP genes simultaneously, NGS can achieve a significantly 
higher rate of successful diagnosis. For example, in two 
recent studies, about 150 RP patients with a variety of in-
heritance forms were examined by NGS based molecular 
diagnosis, revealing an overall diagnosis rate of about 50% 
[19,20]. Secondly, some RP cases follow a digenic inher-
itance model [92], and approximately 50% of cases have an 
unknown inheritance model [82]. NGS can easily be applied 
to these patients in a single step, making it more applicable 
than arrays. Finally, the massive sequencing capacity of 
current NGS machines along with advanced molecular 
bar-coding technology enables sequencing of multiple sam-
ples in parallel [19,20,95–97]. This significantly improves 
throughput while reducing time and cost, making NGS an 
ideal diagnostic platform. 
3.3  NGS based molecular diagnosis in Stargardt dis-
ease 
Stargardt disease is a form of early onset macular degenera-
tion affecting at least 1 in 10000 people [98], with approxi-
mately 31000 affected in the US alone. In Stargardt disease, 
there is a relatively fast degeneration of the macula caused 
by the buildup of oily waste deposits called lipofusin (com-
prised largely of A2E, a vitamin A derivative) in the retinal 
pigment epithelium (RPE) cell layer. This limits interactions 
between photoreceptors and the RPE, hampering the ability 
of photoreceptors to uptake nutrients and perform the visual 
cycle, leading to their death.  
A Stargardt phenotype is only known to be caused by 
mutations in three genes; ABCA4 [99], ELOVL4 [100,101], 
and PROM1 [102]. Of these, ABCA4 is by far the most 
common cause, and the only known gene for recessive 
Stargardt disease. ABCA4 functions as a flippase for 
N-retinylidene-phosphatidylethanolamine and phosphatidyl-      
ethanolamine, moving these compounds from the luminal to 
cytoplasmic side of the photoreceptor outer segment discs 
[103]. Loss of this flippase function leads to the toxic 
buildup of lipofusin [104]. Mutations in ABCA4 also cause 
a large fraction of RP and cone-rod dystrophy cases, and as 
a result ABCA4 is a very well studied gene [98,105].  
It might seem that Stargardt disease is a poor choice for 
NGS based diagnosis, as the power of NGS is not as easily 
justified in a disease that is only typically caused by muta-
tions in one gene. However, even with a huge number of 
known exonic variants (>600 on the current diagnostic chip), 
homozygous or compound heterozygous disease causing 
mutations in ABCA4 are found in only ~30%–40% of pa-
tients using APEX arrays [106,107]. Using NGS based di-
agnosis for ABCA4, a group was able to identify mutations 
in 48% (73/142) of their patients [88], while a more recent 
study using NGS was able to solve 33% of cases that re-
mained unsolved after use of an array [89]. This increase in 
accuracy is due to the ability of NGS to identify novel, rare, 
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detrimental alleles. Polymorphic loci in ABCA4 are 9–400 
times as common as in other retinal disease genes [108], 
generating a lot of variety that can only currently be re-
solved through sequencing. Thus, even in monogenic dis-
eases NGS can offer advantages over array based diagnostic 
methods. 
Regardless of the method used to identify exonic muta-
tions, a molecular diagnosis in Stargardt disease remains 
elusive in a significant fraction of cases. One explanation 
for this phenomenon is that intronic, regulatory and/or 
structural variations, including copy number variations 
(CNVs) and insertion/deletion mutations, account for a 
large portion of disease alleles. This hypothesis has been 
supported by microarray studies, which found ABCA4 
haplotypes segregating with disease in families with no 
identified coding mutations [109]. The genomic size of the 
ABCA4 locus is over 128 kb, making it far too large for it 
to be efficiently Sanger sequenced. However, NGS, through 
the use of a capture array, could be used to probe the entire 
genomic region around ABCA4. Understanding the effects 
of extra-exonic mutations is a topic of current research 
[110]. Improvements are also being made in the ability of 
NGS to detect large deletions and CNVs [111]. 
As our knowledge about other retinal diseases grows, it 
is likely that they will end up like ABCA4 in that many 
cases of the disease will not be explainable by protein cod-
ing variation alone. Improved molecular diagnosis, and its 
clinical advantages, will necessitate sequencing of large 
swaths of the human genome, including the regions con-
taining all known retinal disease genes. By moving toward 
NGS based diagnosis, it is possible to both improve the ef-
ficiency of probing exonic regions and open up whole new 
areas to directed analysis.  
4  Perspectives and conclusion 
Maximal accuracy is a requirement for clinical diagnostics, 
as people base major life decisions on the results of diag-
nostic tests. As shown in the three cases above, NGS im-
proves the accuracy of molecular diagnosis. However, NGS 
is currently more expensive per patient than arrays (though 
the price is rapidly falling) and standards for NGS data 
analysis are still under development. As more causative 
mutations are found and included on diagnostic arrays, their 
accuracy should increase. Will arrays eventually become as 
accurate as NGS? 
One way to consider this question is to graph the number 
of novel mutations found versus the number of people se-
quenced. If the slope of this line remains high after a large 
number of people have been sequenced, it would indicate 
that personal mutations are common, and argue that novel 
mutations will continue to be found for some time to come. 
Disease loci may be in this situation, as purifying selection 
is predicted to keep pathogenic allele frequencies low. This 
question was addressed earlier this year in a predominantly 
European cohort of 14002 people. They were analyzed for 
mutations in 202 drug-targetable genes of clinical signifi-
cance, and it was found that the rate of observing novel 
non-synonymous variants was almost constant with in-
creasing sample size. This finding supports the hypothesis 
that a collection of rare variants is the main driver of disease 
[112], and that arrays may never be able to include a major-
ity of disease causing variants (Figure 3). As a result, NGS 
will likely sustain higher accuracy than array based methods 
in the long term. Aside from accuracy, numerous concerns 
remain about clinical NGS. These include the cost, infra-
structure, business model that will be used, how unclear mu-
tations will be handled, issues regarding the storage and use 
of genetic information, database management, and the devel-
opment of standardized bioinformatics tools for sequence 
data analysis. A recent report by the National Health Service 
of England highlighted many of these concerns, and proposed 
the creation of local diagnostic sequencing centers that 
would service nearby hospitals as a business model [113]. 
Work is currently underway to develop standardized bi-
oinformatics pipelines to ensure repeatability and reliability 
in NGS based diagnosis and proper handling of genomic 
data for large scale use [114]. The cost of NGS has plum-
meted since its introduction [115], and it is likely that the 
cost of sequencing will soon be comparable to the cost of 
other diagnostic methods. Therefore, we expect NGS to 
become common place in clinical diagnostics in this decade  
 
 
Figure 3  Observed polymorphic loci as sample size increases. A, Ob-
served number mutations as sample size increases. The dots are the ob-
served data, while the dotted lines and solid lines are based on jackknife 
projections and hypergeometric expectations, respectively. B, A log scale 
graph allows visualization of up to one million people sequenced. From: 
Nelson M R, et al., “An abundance of rare functional variants in 202 drug 
target genes sequenced in 14002 people”. Science, 2012, 337(6090): 
100-104. Reprinted with permission from AAAS. 
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due to its ability to simultaneously assay broad swaths of 
the genome with great accuracy in a high throughput man-
ner. NGS is poised to lay the groundwork for personalized 
medicine by identifying disease causing genes and patient’s 
individual mutations responsible for their phenotypes. 
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